<DOC>
	<DOCNO>NCT01284218</DOCNO>
	<brief_summary>To examine difference health care utilization cost MDD patient adjunctive aripiprazole therapy MDD patient augmentation therapy .</brief_summary>
	<brief_title>Retrospective Database Study Real World Abilify Outcomes Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>≥1 fill augmentation therapy medication Table 1 identification period 01 January 2005 30 November 2008 . 12 month continuous enrollment medical pharmacy benefit index date ( preindex period ) index date ( postindex period ) . ≥1 medical claim primary International Classification Diseases , 9th Revision , Clinical Modification ( ICD9CM ) diagnosis MDD ( 296.2x , 296.3x , 311.xx ) preindex period . Age ≥18 year year preindex period . No pharmacy claim atypical antipsychotic , mood stabilizer , anxiolytic , anticonvulsant , stimulant , preindex period . No medical claim primary secondary diagnosis nonMDD episodic mood disorder schizophrenia preindex postindex period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>